Search Results - "Kingsley, Edwin C"

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies by Xu, Linlin, Shadman, Mazyar, Flinn, Ian W, Levy, Moshe Y, Porter, Ryan, Burke, John M, Zafar, Syed F, Cultrera, Jennifer L, Misleh, Jamal, Kingsley, Edwin C, Yimer, Habte A, Freeman, Benjamin, Chaudhry, Arvind, Tumula, Praveen K, Gandhi, Mitul D, Crescenzo, Rocco, By, Kunthel, Cohen, Aileen, Chen, Dih-Yih, Idoine, Adam, Manda, Sudhir, Sharman, Jeff P, Ramakrishnan, Vanitha

Get full text

Cancer survivorship in hematologic malignancies: Lifestyle changes after diagnosis by Malalur, Pannaga, Agastya, Manas, Wahi‐Gururaj, Sandhya, Cross, Chad L., Deauna‐Limayo, Delva, Kingsley, Edwin C.

“…Background Studies show that patients make lifestyle changes soon after certain solid tumor diagnoses, suggesting that this may be a teachable moment to…”
Get full text

Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States by Castillo, Jorge J, Kingsley, Edwin C, Narang, Mohit, Yimer, Habte A, Dasanu, Constantin A, Melear, Jason M, Coleman, Morton, Farber, Charles M, Shulman, Jonah, Mantovani, Emily H, Zhang, Xiaowei, Cohen, Aileen, Huang, Jane

“…TABLE 1 Best overall response by investigator assessment in efficacy evaluable population Patients Dose Best overall assessment, n (%) TN (n = 11) R/R (n = 30)…”
Get full text

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies by Savona, Michael R., Kolibaba, Kathryn, Conkling, Paul, Kingsley, Edwin C., Becerra, Carlos, Morris, John C., Rifkin, Robert M., Laille, Eric, Kellerman, Amy, Ukrainskyj, Stacey M., Dong, Qian, Skikne, Barry S.

“…CC‐486 (oral azacitidine) is an epigenetic modifier in clinical development for treatment of hematological cancers. This study of extended CC‐486 dosing…”
Get full text

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma by Phillips, Tycel, Barr, Paul M., Park, Steven I., Kolibaba, Kathryn, Caimi, Paolo F., Chhabra, Saurabh, Kingsley, Edwin C., Boyd, Thomas, Chen, Robert, Carret, Anne-Sophie, Gartner, Elaina M., Li, Hong, Yu, Cindy, Smith, David C.

“…Summary Purpose This first-in-human study evaluated SGN-CD70A, an antibody-drug conjugate (ADC) directed against the integral plasma membrane protein CD70 and…”
Get full text

Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study by Shadman, Mazyar, Flinn, Ian W, Levy, Moshe Y, Porter, Ryan F, Burke, John M, Zafar, Syed F, Misleh, Jamal, Kingsley, Edwin C, Yimer, Habte A, Freeman, Benjamin, Rao, Subramanya S, Chaudhry, Arvind, Tumula, Praveen K, Gandhi, Mitul D, Manda, Sudhir, Chen, Dih-Yih, By, Kunthel, Xu, Linlin, Liu, Ye, Crescenzo, Rocco, Idoine, Adam, Zhang, Xiaoping, Cohen, Aileen, Huang, Jane, Sharman, Jeff P

“…We hypothesised that zanubrutinib, a highly selective next-generation Bruton tyrosine kinase (BTK) inhibitor, would be a safe and active treatment for patients…”
Get full text

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma by Berenson, James R., Hilger, James D., Yellin, Ori, Boccia, Ralph V., Matous, Jeffrey, Dressler, Kenneth, Ghazal, Hassan H., Jamshed, Saad, Kingsley, Edwin C., Harb, Wael A., Noga, Stephen J., Nassir, Youram, Swift, Regina A., Vescio, Robert

“…Panobinostat is a histone deacetylase inhibitor that has shown synergistic preclinical anti-myeloma activity when combined with other agents, recently…”
Get full text

A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor (BTKi) Zanubrutinib in Patients with Waldenström Macroglobulinemia (WM) by Kingsley, Edwin C., Fabre, Shannon, Takai, Motohisa, Cohen, Aileen Cleary, Schneider, Jingjing, Li, Jessica, D'Olimpio, James

“…Background and Significance:Zanubrutinib, a next-generation, selective BTKi, is approved for treatment of WM based on data from the phase 3 ASPEN study…”
Get full text

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies by Shadman, Mazyar, Flinn, Ian W., Kingsley, Edwin C., Freeman, Benjamin B., Levy, Moshe, Farber, Charles M., D'Olimpio, James, Cultrera, Jennifer L., Zhang, Ben, Crescenzo, Rocco J., Idoine, Adam, Zhang, Xiaoping, By, Kunthel, Sharman, Jeff P.

“…Introduction: Bruton tyrosine kinase inhibitors (BTKi) are a mainstay of treatment for B-cell malignancies; however, their use can be limited by adverse events…”
Get full text

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies by Shadman, Mazyar, Flinn, Ian W., Kingsley, Edwin C., Freeman, Benjamin, Levy, Moshe Yair, Holmes, Houston, Farber, Charles M., Chaudhry, Arvind, Crescenzo, Rocco, Idoine, Adam, Zhang, Xiaoping, Cohen, Aileen, By, Kunthel, Huang, Jane, Sharman, Jeff P.

Get full text

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study by Xu, Linlin, Shadman, Mazyar, Flinn, Ian W., Levy, Moshe, Porter, Ryan, Burke, John M., Zafar, Syed F., Cultrera, Jennifer L., Misleh, Jamal, Kingsley, Edwin C., Yimer, Habte A., Freeman, Benjamin B., Chaudhry, Arvind, Tumula, Praveen K., Gandhi, Mitul, Crescenzo, Rocco J., By, Kunthel, Cohen, Aileen Cleary, Idoine, Adam, Manda, Sudhir, Sharman, Jeff P.

“…Introduction:Bruton tyrosine kinase inhibitors (BTKi) have shown remarkable utility in the treatment of B-cell malignancies; yet some patients have experienced…”
Get full text

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies by Xu, Linlin, Shadman, Mazyar, Ponakala, Anusha, Flinn, Ian W., Levy, Moshe Yair, Porter, Ryan, Burke, John M., Zafar, Syed F., Cultrera, Jennifer L., Misleh, Jamal, Kingsley, Edwin C., Yimer, Habte, Freeman, Benjamin, Chaudhry, Arvind, Tumula, Praveen K., Gandhi, Mitul, Cohen, Aileen, Chen, Dih-Yih, Manda, Sudhir, Sharman, Jeff P., Ramakrishnan, Vanitha

Get full text

Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma after Prior Rituximab by Kolibaba, Kathryn S., Shtivelband, Mikhail, Kingsley, Edwin C., Moezi, Mehdi M., Richards, Donald, Sharman, Jeffrey P., Xiaoshu, Feng, Cannan, Megan, Fellague-Chebra, Rafik, Lyons, Roger M.

“…Background: The anti-CD20 monoclonal antibody rituximab, alone or in combination with various chemotherapeutic agents, is the standard of care for patients…”
Get full text

A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) by Goy, Andre, Ramchandren, Radhakrishnan, Ghosh, Nilanjan, Munoz, Javier, Morgan, David S., Dang, Nam H., Knapp, Mark, Delioukina, Maria, Kingsley, Edwin C., Tran, Anh, Ping, Jerry, Beaupre, Darrin M., Neuenburg, Jutta K., Ruan, Jia

“…Background: DLBCL is the most common subtype (30-40%) of non-Hodgkin lymphoma and 50-60% of patients (pts) are cured with standard R-CHOP therapy. Among pts…”
Get full text

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL) by Budde, Lihua E., Halwani, Ahmad, Yasenchak, Christopher A., Farber, Charles Michael, Burke, John M, Fayad, Luis E., Holkova, Beata, Knapp, Mark, Kolibaba, Kathryn S., Advani, Ranjana H, Ansell, Stephen M, Patel-Donnelly, Dipti, Yimer, Habte A., Smith, Scott E., Levy, Moshe Yair, Seetharam, Mahesh, Belada, David, Brooks, Donald, Kingsley, Edwin C., Klein, Leonard M., Wagner-Johnston, Nina, Ruffner, Katherine, Bartlett, Nancy L

“…Introduction DLBCL is the most common lymphoid neoplasm in adults (Swerdlow 2016). While durable CRs are achieved in approximately 70% of patients (pts) with…”
Get full text

CC-486 in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response by Savona, Michael R., Kolibaba, Kathryn, Conkling, Paul, Kingsley, Edwin C., Becerra, Carlos, Morris, John, Rifkin, Robert M., Laille, Eric, Kellerman, Amy, Ukrainskyj, Stacey M., Dong, Qian, Skikne, Barry S.

“…Background: CC-486 is an oral formulation of the epigenetic modifier, azacitidine, in clinical development for treatment (Tx) of hematological cancers. Part 1…”
Get full text

Acute Promyelocytic Leukemia by Kingsley, E C, Durie, B G, Garewal, H S

“…Acute promyelocytic leukemia (APL) is a subtype of acute myelogenous leukemia frequently associated with disseminated intravascular coagulation (DIC). Data on…”
Get full text

5-Fluorouracil dermatitis prophylaxis with a nicotine patch by Kingsley, E C

Get full text

Prolonged survival in patients with treatment-related leukemia by Kingsley, E C, Durie, B G

“…We summarize the findings in 2 patients with treatment-related acute leukemia, who have had prolonged disease-free survival (62 and 84 months, respectively)…”
Get more information

Trisomy 14: a new entity within acute nonlymphocytic leukemia by Meloni-Balliet, A, Morgan, R, Poth, J L, Kingsley, E C, Sandberg, A A

“…Three cases of acute nonlymphocytic leukemia with trisomy 14 as the sole chromosome abnormality are presented and it is suggested that this type of trisomy,…”
Get more information